Document is current

Article History

Received: 12 November 2023

Revised: 29 January 2024

Accepted: 11 April 2024

First Online: 23 April 2024

Competing interests

: None related to the paper. AM, RPM, SC, DK, and ST have no financial disclosures. ShC is a member of the Editorial board. SS received consultancy fees from Bayer, Allergan, Novartis Pharma AG, Roche, Boehringer Ingelheim, Optos, Apellis, Oxurion, Oculis and Heidelberg Engineering and is a member of the Eye editorial board. VC is an employee of Janssen R&D and previously of Boehringer Ingelheim. AG is an employee of Boehringer Ingelheim. TCNY is an employee of Boehringer Ingelheim. BB is in the advisory board and received international conference attendance sponsored by Novartis and Bayer. GM has conducted consultancy-advisory boards for Novartis, Bayer and Allergan, received educational travel grants from Novartis, Bayer, Allergan. IP has received lecture fees from Allergan, Bayer, Heidelberg and Novartis, consultancy fees from Allergan, Alimera, Bayer and Novartis and travel fees from Allergan, Bayer and Novartis. FG has received honorarium for consultancy-advisory boards from Alimera, Allergan, Bayer, Novartis, Oxford BioElectronics, Roche; educational travel grants from Allergan, Bayer, Novartis and is a member of the Eye editorial board. MM has received lecture and advisory board honoraria from Bayer and Novartis and an educational travel grant from Bayer. RG has conducted consultancy-advisory boards for Novartis, Bayer and Allergan, Alimera, Santen, received educational travel grants from Novartis, Bayer, Allergan, Heidelberg Engineering. JT is a consultant for Bayer and Novartis, received grant support from Bayer, Novartis and Heidelberg Engineering, and is involved in research for Allergan, Roche, Bayer, Novartis and Boehringer-Ingelheim. AK received travel support from Novartis, Bayer, and Allergan, and speaker fees from Allergan and Bayer.